[Federal Register Volume 65, Number 97 (Thursday, May 18, 2000)]
[Notices]
[Pages 31578-31579]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-12547]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by agencies of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by contacting Vasant Gandhi, 
J.D., Ph.D., at the Office of Technology Transfer, National Institutes 
of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 
20852-3804; telephone: 301/496-7056 ext. 224; fax: 301/402-0220; e-
mail: <a href="/cdn-cgi/l/email-protection#8cfaebb8b4fdcce2e5e4a2ebe3fa"><span class="__cf_email__" data-cfemail="2b5d4c1f135a6b454243054c445d">[email protected]</span></a>. A signed Confidential Disclosure Agreement will be 
required to receive copies of the patent applications.

Peptides That Inhibit the Binding of Human Monocyte Chemoattractant 
Protein-1 (MCP-1) to Its Receptor CCR2

Teizo Yoshimura (NCI)
DHHS Reference No. E-235-99/0 filed 30 Nov 1999

    MCP-1 is a chemoattractant protein and is a member of a family of 
proinflammatory cytokines called chemokines. Chemokines are of interest 
because of their ability to attract and activate specific leukocyte 
subsets to the exclusion of others. In particular, MCP-1 is capable of 
attracting monocytes but not neutrophils. The inventors isolated 
peptides with an antibody (E11) that immunoreacts with MCP-1. One such 
peptide may be useful in blocking the interaction of MCP-1 and its 
receptor CCR2 which may disrupt the formation and/or progression of a 
variety of disease states. MCP-1 has been detected in lesions of 
atherosclerosis, rheumatoid arthritis, pulmonary fibrosis and tumors 
such as malignant fibrous histiocytoma, malignant glioma, meningioma or 
melanoma.

Inhibition of ABC Transporters by Transmembrane Domain Analogs

Nadya Tarasova, Michael M Gottesman, Christine Hrycyna,
Christopher J Michejda (NCI)
DHHS Reference No. E-019-00/0 filed 18 Nov 1999

    ABC transporters contain multiple transmembrane domains and are 
involved in the translocation of a variety of substrates across cell 
membranes. Upregulation of these transporters contributes to multiple 
drug resistance in cancer chemotherapy. The inventors have found that 
the P-gp (P-glycoprotein or Multiple Drug Resistance Protein-1) can be 
inhibited by properly substituted peptides corresponding to one of the 
transmembrane domains. Such inhibition can be used to enhance the 
activity of cancer chemotherapy in resistant tumors.

[[Page 31579]]

Assay for the Detection of a Variety of Tumors in Biological 
Specimens

Larry W. Fisher, Neal S. Fedarko, Marian F. Young (NICHD)
DHHS Reference No. E-173-98/0 filed 09 Apr 1999

    The inventors have developed methods and reagents for the detection 
of bone sialoprotein (BSP) in biological samples. The technology 
relates to the disruption of a serum complex that masks the majority of 
BSP from established detection systems. Furthermore, there is evidence 
that there may be a more acidic form of BSP secreted not by normal 
bone, but only by tumors. Detection of BSP in serum may be a good 
marker of various bone diseases and a variety of cancers including 
breast, prostate, lung, and thyroid.

    Dated: April 25, 2000.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 00-12547 Filed 5-17-00; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>